In particular, there is now a body of evidence implicating the propagation and release of tau as a disease mechanism in AD and other tauopathies [38–41]; suggesting immunotherapy intervention with antibodies could prevent the propagation of such pathology. Here, MAPT is linked to Alzheimer disease.